- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 26, 2024
Deals
Sarepta broadens pipeline via siRNA deal with Arrowhead, paying $825M up front
CEO Ingram sees “the one significant strategic transaction” to transform Sarepta’s future, while Arrowhead preps for first-ever launch
BioCentury | Apr 25, 2023
Product Development
Viehbacher takes first steps in Biogen redesign
Stops development of high-risk stroke programs, exits ophthalmology research
BioCentury | May 23, 2022
Product Development
Biohaven looking at subgroup data after spinocerebellar ataxia miss
Biotech engaging with FDA to determine path forward for rare disease program destined for spinout after Pfizer deal
BioCentury | Oct 20, 2021
Deals
Quick Takes: Singapore’s Cerecin raises $40M from enlarged syndicate
Crinetics spins out radiotherapeutics company, IO Biotech, Calithera, Sana and more
BioCentury | May 20, 2021
Deals
Neuro deal flow: pharmas pinning hopes on new modalities, delivery technologies
The last three years of deals prioritize new modalities against known targets and CNS entry over discovery of new targets
BioCentury | Oct 24, 2020
Translation in Brief
UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more
BioCentury’s roundup of translational news
BioCentury | May 4, 2017
Targets & Mechanisms
The polyQ diet
How polyQ tracts block autophagy in neurodegenerative diseases
Items per page:
1 - 10 of 15